Study outcome | Unadjusted HR (95% CI) | P value | Adjusted model 1* HR (95% CI) | P value | Adjusted model 2† HR (95% CI) | P value |
Primary endpoint (n=456) | 1.23 (1.14 to 1.32) | <0.001 | 1.16 (1.06 to 1.29) | 0.002 | 1.16 (1.05 to 1.29) | 0.002 |
Heart failure hospitalisation (n=53) | 1.60 (1.37 to 1.87) | <0.001 | 1.18 (0.94 to 1.50) | 0.162 | n.a. | |
CV death (n=63) | 1.50 (1.31 to 1.77) | <0.001 | 1.42 (1.14 to 1.79) | 0.002 | n.a. | |
Combined CV death and hospitalised HF (n=105) | 1.49 (1.34 to 1.66) | <0.001 | 1.29 (1.09 to 1.54) | 0.004 | 1.33 (1.11 to 1.60) | 0.002 |
All-cause mortality (n=121) | 1.33 (1.17 to 1.51) | <0.001 | 1.34 (1.13 to 1.58) | 0.001 | 1.36 (1.15 to 1.62) | <0.001 |
Combined all-cause mortality and hospitalised HF (n=153) | 1.40 (1.26 to 1.56) | <0.001 | 1.29 (1.12 to 1.49) | <0.001 | 1.32 (1.14 to 1.53) | <0.001 |
Non-fatal myocardial infarction (n=26) | 1.40 (1.07 to 1.83) | 0.016 | n.a. | n.a. |
Unadjusted and adjusted time-varying Cox regression models. Results of 1 SD higher in-study LV mass–wall stress–heart rate are presented as HR and 95% CI.
*Adjusted for sex, baseline hypertension and age, and time-varying body mass index, LV hypertrophy, LV ejection fraction and peak jet velocity.
†Adjusted also for prevalent atrial fibrillation use of beta-blocker treatment at baseline and time-varying left atrial diameter, stroke volume index and serum creatinine.
CV, cardiovascular; HF, heart failure; LV, left ventricular; n.a., not applicable.